Micromet, Inc. Reports First Quarter 2008 Financi...( BETHESDA Md. May 8 /- Micromet In...),Health

BETHESDA, Md., May 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2008.

Summary of Recent Events:

-- In April, Micromet announced the initiation of the first phase 1

clinical trial with its BiTE(R) antibody MT110. The study will explore

the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity

of MT110 in patients with lung cancer and patients with

gastrointestinal cancer. MT110 targets the epithelial cell adhesion

molecule (EpCAM or CD326), which is highly expressed on colon, lung,

breast, prostate, ovarian, gastric and pancreas cancers and on cancer

stem cells of colon, breast, prostate and pancreas cancers. Cancer

stem cells are believed to cause metastases and recurrence of these

cancers.

-- Also in April, Micromet presented five posters at the American

Association for Cancer Research (AACR) showing recent progress on the

company's proprietary BiTE antibody platform and new BiTE antibodies:

-- Commercial anti-cancer antibodies Herceptin(R), Erbitux(R) and

Vectibix(R) and asthma antibody Xolair(R) can be converted to highly

potent BiTE antibodies.

-- Animal data indicate feasibility of subcutaneous administration of

BiTE antibodies MT103 and MT110.

-- Animal data provided proof of concept for a BiTE antibody targeting

CD33 with potential use in the treatment of acute myelogenic

leukemia (AML), and a BiTE antibody targeting MCSP with potential

use in the treatment of melanoma.

-- Animal data suggest a therapeutic window of a BiTE antibody

targeting EpCAM in a rele
'/>"/>